CAR-T: Recent Episodes
Bella Smith
The target tumor cells are labeled with specific fluorescent cytoplasmic reagent, the live cells can be imaged and monitored at real-time level to measure the tumor cell lysis. The reagent is safe for cells at optimized concentration, and fluorescence measurements can be accurately performed for short-term experiments, as the reagent will be diluted with cell proliferation. In addition, the ratio of target tumor cells and CAR-T cells can be optimized in the assay. https://www.creative-biolabs.com/car-t/t-cell-mediated-tumor-cell-lysis-assay.htm
Altering the specificity of T cell receptor (TCR) is one of the popular strategies to genetically modify T cells to enhance the tumor-killing activity of T cells. From a tumor-reactive T cell or active anti-tumor T-cell antigens, the appropriate target sequence is introduced to modify T cells to target a broad range of tumors with improved specificity. https://www.creative-biolabs.com/car-t/cellrapeutics-tcr-technology.htm
In patient's T Cell Isolation, flow cytometry analysis of isolated blood products ensures that a sufficient number of healthy and functional T cells being used for processing and re-infusion. https://www.creative-biolabs.com/car-t/flow-cytometry-application-in-car-t-system.htm
T cell infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors are crucial for tumor clearance. T cell infiltration assays ensure the functional T cells are located in tumor microenvironment to display humoral or cellular immunity both in vitro and in vivo. https://www.creative-biolabs.com/car-t/enhancement-or-inhibition-of-t-cell-response-assays.htm
CAR-T cell preclinical in vivo animal testing performed in xenograft murine models derived by well-defined cell lines or primary human tumor cells. Immunodeficient mice, lacking of effective innate immunity for the absence of B cells, T cells, or NK cells, are the optimal animal models for engraftment of tumor cells and evaluation of CAR-T cells. https://www.creative-biolabs.com/car-t/car-t-preclinical-in-vivo-assay.htm
Electroporation transfer is emerged as a powerful tool for the genetic modification of diverse cell types based on the transient disruption of cell membrane via exposure to an electric field, which allows charged molecules to enter the cell. For instance, the square-wave pulse-based new electroporation devices, such as Lonza Nucleofector II electroporation system, manifests a high efficiency in the genetic modification of T cells with proprietary electroporation buffers and electric parameters. https://www.creative-biolabs.com/car-t/gene-packaging-delivery.htm
Notably, several CAR-T libraries have been generated not only for blood cancer antigen CD19, but also for solid tumors against different antigens, such as Her2, Her3, EGFR, FGFR1, VEGFR, etc. The selected stable clones can be used in clinic trials immediately, thus making this technology more powerful and attractive in chimeric antigen receptor t cell therapy. https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm
In a narrow sense of cancer biomarker, it is limited to proteins the most used to challenge in the clinical applications, especially in the CAR-T therapy. Specifically, a cancer biomarker of the CAR-T provides the most prominent signal of cancer cells for distinguishing from normal cells and the most effective CAR T target for immune recognition and destruction. https://www.creative-biolabs.com/car-t/biomarker-identification-selection.htm
In general, the T cell phagocytosis assay can be divided into two categories, in vivo and in vitro. Both of them are always based on fluorescence. In vivo assay has advantages to be more useful and credible, while in vitro phagocytosis assay could give insights during an early stage in a very short timeline. https://www.creative-biolabs.com/car-t/cellrapeutics-phagocytosis-assay.htm
The typical structure of a CAR molecule includes a single chain variable fragment (scFv), a spacer, a transmembrane domain (TM) and an intracellular signaling domain. The scFv is derived from monoclonal antibody (mAb), which can specifically recognize the target protein on tumor surface and subsequently transduct activation signal into chimeric antigen receptor t-cells. https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm
Flow cytometry is a widely used laser- or impedance-based method for CAR T Characterization by analyzing the expression of cell surface and intracellular molecules, characterizing and defining different cell types in a heterogeneous cell population, assessing the purity of isolated subpopulations and analyzing cell size and volume. https://www.creative-biolabs.com/car-t/flow-cytometry-application-in-car-t-system.htm
Single-cell sequencing (SCS) can be employed for analyzing the genetic polymorphisms of individual cells at a genome-wide level. Basically,there are three steps including obtaining single cell of interest, extraction and amplification of genetic materials, and descriptive analysis from CAR sequencing data. https://www.creative-biolabs.com/car-t/single-cell-analysis-for-car-t-cell.htm
In an organism’s immune system, T Cell Phagocytosis is a principal mechanism used to eliminate pathogens and clear cell debris. In other words, it is crucial in fighting infections, as well as in maintaining healthy tissues. https://www.creative-biolabs.com/car-t/cellrapeutics-phagocytosis-assay.htm
In T Cell Isolation, flow cytometry analysis of isolated blood products is provided to ensure that a sufficient number of healthy and functional T cells being used for processing and re-infusion. https://www.creative-biolabs.com/car-t/flow-cytometry-application-in-car-t-system.htm
Based on the stimuli and the achieved transcriptional changes, the M2 macrophages can be classified into four subdivisions - M2a, M2b, M2c, and M2d. In this assay, except for different macrophage polarization by adding certain stimuli, verification of each polarized macrophage-based on the distinctly expressed surface markers and/or produced cytokines is available. https://www.creative-biolabs.com/car-t/macrophage-polarization-assay.htm
SCS can be employed for analyzing the genetic polymorphisms of individual cells at a genome-wide level. Basically,there are three steps including obtaining single cell of interest, extraction and amplification of genetic materials, and descriptive analysis from CAR sequencing data. https://www.creative-biolabs.com/car-t/single-cell-analysis-for-car-t-cell.htm
We have high qualified groups and advanced technologies to perform TCR engineering services covering every unit of manufacturing and delivery pipeline. From a tumor-reactive T cell or active anti-tumor T-cell antigens, the appropriate target sequence is introduced to modify T cells to target a broad range of tumors with improved specificity. With engineering TCR construction and a series of assay, such as transgene expression, TCR/CD3 stability, lymphocyte antigen reactivity and cytotoxicity, animal experiments, etc., we provide cGMP-compliant TCR products for preclinical and clinical trials. Learn more about TCR T cells. https://www.creative-biolabs.com/car-t/cellrapeutics-tcr-technology.htm
The typical structure of a chimeric antigen receptor molecule includes a single chain variable fragment (scFv), a spacer, a transmembrane domain (TM) and an intracellular signaling domain. The scFv is derived from monoclonal antibody (mAb), which can specifically recognize the target protein on tumor surface and subsequently transduct activation signal into CAR-T cell.
Due to the linkage between the T cell activation and the expression and function of the CARs, we would obtain functional CARs with high affinities ranging from 10 pmol to nmol. Notably, we have generated several CAR-T libraries not only for blood cancer antigen CD19, but also for solid tumors against different antigens, such as Her2, Her3, EGFR, FGFR1, VEGFR, etc. The selected stable clones can be used in clinic trials immediately, thus making this CAR T technology more powerful and attractive in CAR-T cell immunotherapy. https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm
The TCR is a molecule existed on the surface of T cells, or T lymphocytes. Its responsibility is to recognize fragments of antigen to provide peptides bound to major histocompatibility complex (MHC) molecules. Bispecific TCR molecules can leverage the body’s immune system by regulating the T-cell response towards cancer cells with specific tumor targets. There are two domains of our bispecific T-cell receptor. One of them is an affinity-maturated and highly selective TCR domain that can recognize and bind to a tumor-specific peptide target presented in the context of HLA class I receptor, the other is a T-cell recruiting antibody domain directed against CD3 or other immuno-modulating T-cell surface proteins. https://www.creative-biolabs.com/car-t/bispecific-tcr-development-service.htm